Refine
Has Fulltext
- yes (61)
Is part of the Bibliography
- yes (61)
Year of publication
Document Type
- Journal article (61)
Language
- English (61) (remove)
Keywords
- ischemic stroke (6)
- cochlear implantation (3)
- mechanical thrombectomy (3)
- neutrophils (3)
- thrombo-inflammation (3)
- 3D fluoroscopy (2)
- Childhood medulloblastoma (2)
- Clinical Neuroradiology (2)
- Radiotherapy (2)
- acute ischemic stroke (2)
- aortic arch (2)
- atherosclerosis (2)
- cerebellar tDCS (2)
- chemotherapy (2)
- editorial (2)
- fpVCT (2)
- immunohistochemistry (2)
- intraoperative imaging (2)
- ischemic penumbra (2)
- magnetic resonance imaging (2)
- middle cerebral artery occlusion (2)
- mouse (2)
- multiple sclerosis (2)
- neurology (2)
- radiotherapy (2)
- split-belt treadmill (2)
- stroke (2)
- surgery (2)
- temporal bone (2)
- three-dimensional imaging (2)
- 3 D rotational fluoroscopy (1)
- 3D analysis (1)
- 4D flow (1)
- 4D flow MRI (1)
- APERIO (1)
- APERIO Hybrid (1)
- AT/RT (1)
- Activation (1)
- Adolescents (1)
- Alemtuzumab (1)
- Alzheimer’s dementia (1)
- Atherosclerosis, intracranial arteries (1)
- B cells (1)
- B7-H1 Antigen (1)
- Brain atrophy (1)
- CD52 (1)
- CDL (1)
- CMR (1)
- CNS (1)
- CNS imaging (1)
- COVID-19 (1)
- CT (1)
- CTLA-4 Antigen (1)
- CXCL4 (1)
- CXCL7 (1)
- Chemotherapy (1)
- Childrens-cancer (1)
- Chronic heart failure (1)
- Cisplatin (1)
- Clinical Genetics (1)
- Clinical trial (1)
- Cochlear duct length (1)
- Cochlear planning software (1)
- Cognitive decline (1)
- Covid-19 (1)
- DWI (1)
- Down-regulation (1)
- Drug Therapy, Combination (1)
- EAE (1)
- EU‐RHAB Registry (1)
- Extraocular eye muscles (1)
- Fabry disease (1)
- Fibroblasts (1)
- GFAP (1)
- Gene (1)
- Glial fibrillary acidic protein (1)
- HD (1)
- HMGB1 (1)
- High-dose chemotherapy (1)
- Induced apoptosis (1)
- Lines (1)
- MPI (1)
- MPS (1)
- MR neurography (1)
- MRI (1)
- MS (1)
- MSCT (1)
- MTX (1)
- Medulloblastoma (1)
- Melanoma-cells (1)
- Memory dysfunction (1)
- Meniere’s disease (1)
- Metastases (1)
- Mucopolysaccharidosis IIIa (1)
- NAP-2 (1)
- NETs (1)
- NOAC (1)
- Orai2 (1)
- PET/CT (1)
- PF4 (1)
- PWV (1)
- Paediatric (1)
- Parkinson’s disease (1)
- Phase II trials (1)
- Phase-II (1)
- Primitive neuroectodermal (1)
- Programmed Cell Death 1 Receptor (1)
- R-CHOP (1)
- Recurrent medulloblastoma (1)
- Reirradiation (1)
- Relapse (1)
- Rhabdoid 2007 (1)
- Rhabdomyosarcoma (1)
- Secondary tumours (1)
- Skin Neoplasms (1)
- Suprascapular nerve (1)
- Survival (1)
- T-cells (1)
- Therapy (1)
- Treatment (1)
- Trial (1)
- Tumors (1)
- WSS (1)
- adverse events (1)
- age (1)
- anatomy (1)
- aneurysm (1)
- aneurysm surgery (1)
- angiography (1)
- balance (1)
- biochemical assays (1)
- biomarker (1)
- biomedical engineering (1)
- blood–brain barrier (1)
- bone imaging (1)
- brain cancer (1)
- brain endothelium (1)
- carotid atherosclerosis (1)
- carotid stenosis (1)
- carotid ultrasound (1)
- cerebral ischemia (1)
- cerebral vasospasm (1)
- cerebrovascular disorders (1)
- cervical dystonia (1)
- characterization and analytical techniques (1)
- chemokines (1)
- childhood cancer (1)
- children (1)
- cholinergic activity (1)
- classification (1)
- clinical trials (1)
- clip control (1)
- cognitive impairment (1)
- collateral circulation (1)
- compression syndrome (1)
- computed tomography (1)
- consolidation (1)
- continuous theta burst stimulation (cTBS) (1)
- contrast (1)
- cortical excitability (1)
- cortical silent period (1)
- crosslinked coating (1)
- degree of stenosis (1)
- diabetic polyneuropathy (1)
- diagnosis (1)
- diagnosis in Fabry disease (1)
- diagnostic delay (1)
- diffuse large B-cell lymphoma (1)
- disease risk-factors (1)
- dorsal root ganglion (1)
- editorial board (1)
- edoxaban (1)
- electrical and electronic engineering (1)
- electromagnetic navigation (1)
- electromyographic (1)
- encephalopathy (1)
- endoglin (1)
- endotheliitis (1)
- experimental stroke (1)
- facial nerve (1)
- fibromyalgia syndrome (1)
- fiducial registration error (1)
- flexible CO2 laser (1)
- flow (1)
- flow dynamics (1)
- fluoroscopy (1)
- frameless systems (1)
- functional MRI (1)
- gait (1)
- gene variant (1)
- genotype-phenotype correlation (1)
- genotype/phenotype correlation (1)
- german multicenter (1)
- giant cell arteritis (1)
- glycoprotein VI (1)
- glycoprotein receptor Ib (1)
- glycoprotein receptor Ibα (1)
- guality-of-life (1)
- heart failure (1)
- hemorrhagic transformation (1)
- hepatitis B virus (1)
- hypoxia (1)
- image quality (1)
- imaging (1)
- imaging agents (1)
- imaging changes (1)
- integrin α2 (1)
- interelectrode-distance (1)
- intracranial bleeding (1)
- intraoperative (1)
- intraventricular therapy (1)
- journal (1)
- jugular paraganglioma (1)
- large artery vasculitis (1)
- large vessel occlusion (1)
- laser surgery (1)
- lateral skull base (1)
- length of stenosis (1)
- leukocytes (1)
- levodopa-induced dyskinesia (1)
- locomotor adaptation (1)
- long-term survivors (1)
- lymphoma (1)
- lysosomal storage disease (1)
- magnetic properties (1)
- magnetic properties and materials (1)
- magnetic resonance neurography (1)
- mapping (1)
- mass index (1)
- medical imaging (1)
- medulloblastoma (1)
- mice (1)
- microscopy (1)
- motor-evoked potentials (MEP) (1)
- nanoparticles (1)
- neck circumference (1)
- neurofilament light chain (1)
- neurological complications (1)
- neuropathic pain (1)
- neuropathy (1)
- neurosurgery (1)
- neurovascular disorders (1)
- onset craniopharyngioma (1)
- ophthalmic artery (1)
- optic nerve (1)
- orbit (1)
- otology (1)
- outcome (1)
- p.R245H (1)
- p.S298P (1)
- pediatric brain tumor (1)
- pediatric low‐grade glioma (1)
- peripheral nerve involvement (1)
- peripheral nervous system (1)
- phosphorylated tau protein (1)
- plaque (1)
- plaque characteristics (1)
- platelets (1)
- post-processing (1)
- prognosis (1)
- progression (1)
- proton beam therapy (1)
- pulse wave velocity (1)
- quantification (1)
- radial (1)
- re-irradiation (1)
- recombinant tissue-type plasminogen activator (1)
- recurrent (1)
- refractory (1)
- renal function (1)
- reperfusion injury (1)
- research activity (1)
- risk of fall (1)
- saccotomy (1)
- secondary reconstruction (1)
- self-navigation (1)
- shedding (1)
- shoulder neurolysis (1)
- software (1)
- stent-retriever device (1)
- stereotaxy (1)
- subarachnoid hemorrhage (1)
- subcutaneous adipose-tissue (1)
- suprascapular notch (1)
- surgical management of paraganglioma (1)
- tMCAO (1)
- thrombemboli (1)
- thromboemboli (1)
- to-height ratio (1)
- tomography (1)
- transcranial magnetic simulation (TMS) (1)
- transient middle cerebral artery occlusion (1)
- tympanic paraganglioma (1)
- tympanojugular paraganglioma (1)
- vasa vasorum (1)
- vertebral artery (1)
- vessel diameter (1)
- vessel patency (1)
- vestibular aqueduct (VA) (1)
- visceral adiposity (1)
- wall shear stress (1)
Institute
- Institut für diagnostische und interventionelle Neuroradiologie (ehem. Abteilung für Neuroradiologie) (61) (remove)
Sonstige beteiligte Institutionen
Growth, ageing and atherosclerotic plaque development alter the biomechanical forces acting on the vessel wall. However, monitoring the detailed local changes in wall shear stress (WSS) at distinct sites of the murine aortic arch over time has been challenging. Here, we studied the temporal and spatial changes in flow, WSS, oscillatory shear index (OSI) and elastic properties of healthy wildtype (WT, n = 5) and atherosclerotic apolipoprotein E-deficient (Apoe\(^{−/−}\), n = 6) mice during ageing and atherosclerosis using high-resolution 4D flow magnetic resonance imaging (MRI). Spatially resolved 2D projection maps of WSS and OSI of the complete aortic arch were generated, allowing the pixel-wise statistical analysis of inter- and intragroup hemodynamic changes over time and local correlations between WSS, pulse wave velocity (PWV), plaque and vessel wall characteristics. The study revealed converse differences of local hemodynamic profiles in healthy WT and atherosclerotic Apoe\(^{−/−}\) mice, and we identified the circumferential WSS as potential marker of plaque size and composition in advanced atherosclerosis and the radial strain as a potential marker for vascular elasticity. Two-dimensional (2D) projection maps of WSS and OSI, including statistical analysis provide a powerful tool to monitor local aortic hemodynamics during ageing and atherosclerosis. The correlation of spatially resolved hemodynamics and plaque characteristics could significantly improve our understanding of the impact of hemodynamics on atherosclerosis, which may be key to understand plaque progression towards vulnerability.
CNS imaging characteristics in fibromyalgia patients with and without peripheral nerve involvement
(2022)
We tested the hypothesis that reduced skin innervation in fibromyalgia syndrome is associated with specific CNS changes. This prospective case–control study included 43 women diagnosed with fibromyalgia syndrome and 40 healthy controls. We further compared the fibromyalgia subgroups with reduced (n = 21) and normal (n = 22) skin innervation. Brains were analysed for cortical volume, for white matter integrity, and for functional connectivity. Compared to controls, cortical thickness was decreased in regions of the frontal, temporal and parietal cortex in the fibromyalgia group as a whole, and decreased in the bilateral pericalcarine cortices in the fibromyalgia subgroup with reduced skin innervation. Diffusion tensor imaging revealed a significant increase in fractional anisotropy in the corona radiata, the corpus callosum, cingulum and fornix in patients with fibromyalgia compared to healthy controls and decreased FA in parts of the internal capsule and thalamic radiation in the subgroup with reduced skin innervation. Using resting-state fMRI, the fibromyalgia group as a whole showed functional hypoconnectivity between the right midfrontal gyrus and the posterior cerebellum and the right crus cerebellum, respectively. The subgroup with reduced skin innervation showed hyperconnectivity between the inferior frontal gyrus, the angular gyrus and the posterior parietal gyrus. Our results suggest that the subgroup of fibromyalgia patients with pronounced pathology in the peripheral nervous system shows alterations in morphology, structural and functional connectivity also at the level of the encephalon. We propose considering these subgroups when conducting clinical trials.
Atypical teratoid rhabdoid tumors (AT/RT) are characterized by mutations and subsequent inactivation of SMARCB1 (INI1, hSNF5), a predilection for very young children and an unfavorable outcome. The European Registry for rhabdoid tumors (EU‐RHAB) was established to generate a common European database and to establish a standardized treatment regimen as the basis for phase I/II trials. Thus, genetic analyses, neuropathologic and radiologic diagnoses, and a consensus treatment regimen were prospectively evaluated. From 2005 to 2009, 31 patients with AT/RT from four countries were recruited into the registry study Rhabdoid 2007 and treated with systemic and intraventricular chemotherapy. Eight patients received high‐dose chemotherapy, 23 radiotherapy, and 17 maintenance therapy. Reference evaluations were performed in 64% (genetic analyses, FISH, MLPA, sequencing) up to 97% (neuropathology, INI1 stain). Germ‐line mutations (GLM) were detected in 6/21 patients. Prolonged overall survival was associated with age above 3 years, radiotherapy and achievement of a complete remission. 6‐year overall and event‐free survival rates were 46% (±0.10) and 45% (±0.09), respectively. Serious adverse events and one treatment‐related death due to insufficiency of a ventriculo peritoneal shunt (VP‐shunt) and consecutive herniation were noted. Acquisition of standardized data including reference diagnosis and a standard treatment schedule improved data quality along with a survival benefit. Treatment was feasible with significant but manageable toxicity. Although our analysis is biased due to heterogeneous adherence to therapy, EU‐RHAB provides the best available basis for phase I/II clinical trials.
Patients with atrial fibrillation and previous ischemic stroke (IS) are at increased risk of cerebrovascular events despite anticoagulation. In these patients, treatment with non-vitamin K oral anticoagulants (NOAC) such as edoxaban reduced the probability and severity of further IS without increasing the risk of major bleeding. However, the detailed protective mechanism of edoxaban has not yet been investigated in a model of ischemia/reperfusion injury. Therefore, in the current study we aimed to assess in a clinically relevant setting whether treatment with edoxaban attenuates stroke severity, and whether edoxaban has an impact on the local cerebral inflammatory response and blood–brain barrier (BBB) function after experimental IS in mice. Focal cerebral ischemia was induced by transient middle cerebral artery occlusion in male mice receiving edoxaban, phenprocoumon or vehicle. Infarct volumes, functional outcome and the occurrence of intracerebral hemorrhage were assessed. BBB damage and the extent of local inflammatory response were determined. Treatment with edoxaban significantly reduced infarct volumes and improved neurological outcome and BBB function on day 1 and attenuated brain tissue inflammation. In summary, our study provides evidence that edoxaban might exert its protective effect in human IS by modulating different key steps of IS pathophysiology, but further studies are warranted.
During ischemic stroke, infarct growth before recanalization diminishes functional outcome. Hence, adjunct treatment options to protect the ischemic penumbra before recanalization are eagerly awaited. In experimental stroke targeting two different pathways conferred protection from penumbral tissue loss: (1) enhancement of hypoxic tolerance of neurons by deletion of the calcium channel subunit Orai2 and (2) blocking of detrimental lymphocyte–platelet responses. However, until now, no preclinical stroke study has assessed the potential of combining neuroprotective with anti-thrombo-inflammatory interventions to augment therapeutic effects. We induced focal cerebral ischemia in Orai2-deficient (Orai2\(^{-/-}\)) mice by middle cerebral artery occlusion (MCAO). Animals were treated with anti-glycoprotein Ib alpha (GPIbα) Fab fragments (p0p/B Fab) blocking GPIbα–von Willebrand factor (vWF) interactions. Rat immunoglobulin G (IgG) Fab was used as the control treatment. The extent of infarct growth before recanalization was assessed at 4 h after MCAO. Moreover, infarct volumes were determined 6 h after recanalization (occlusion time: 4 h). Orai2 deficiency significantly halted cerebral infarct progression under occlusion. Inhibition of platelet GPIbα further reduced primary infarct growth in Orai2\(^{-/-}\) mice. During ischemia–reperfusion, upon recanalization, mice were likewise protected. All in all, we show that neuroprotection in Orai2\(^{-/-}\) mice can be augmented by targeting thrombo-inflammation. This supports the clinical development of combined neuroprotective/anti-platelet strategies in hyper-acute stroke.
Objective: To investigate the association between levodopa‐induced dyskinesias and striatal cholinergic activity in patients with Parkinson's disease.
Methods: This study included 13 Parkinson's disease patients with peak‐of‐dose levodopa‐induced dyskinesias, 12 nondyskinetic patients, and 12 healthy controls. Participants underwent 5‐[\(^{123}\)I]iodo‐3‐[2(S)‐2‐azetidinylmethoxy]pyridine single‐photon emission computed tomography, a marker of nicotinic acetylcholine receptors, [\(^{123}\)I]N‐ω‐fluoropropyl‐2β‐carbomethoxy‐3β‐(4‐iodophenyl)nortropane single‐photon emission computed tomography, to measure dopamine reuptake transporter density and 2‐[\(^{18}\)F]fluoro‐2‐deoxyglucose positron emission tomography to assess regional cerebral metabolic activity. Striatal binding potentials, uptake values at basal ganglia structures, and correlations with clinical variables were analyzed.
Results: Density of nicotinic acetylcholine receptors in the caudate nucleus of dyskinetic subjects was similar to that of healthy controls and significantly higher to that of nondyskinetic patients, in particular, contralaterally to the clinically most affected side.
Interpretation: Our findings support the hypothesis that the expression of dyskinesia may be related to cholinergic neuronal excitability in a dopaminergic‐depleted striatum. Cholinergic signaling would play a role in maintaining striatal dopaminergic responsiveness, possibly defining disease phenotype and progression.
Background and Purpose: Internal carotid artery stenosis (ICAS)≥70% is a leading cause of ischemic cerebrovascular events (ICVEs). However, a considerable percentage of stroke survivors with symptomatic ICAS (sICAS) have <70% stenosis with a vulnerable plaque. Whether the length of ICAS is associated with high risk of ICVEs is poorly investigated. Our main aim was to investigate the relation between the length of ICAS and the development of ICVEs.
Methods: In a retrospective cross-sectional study, we identified 95 arteries with sICAS and another 64 with asymptomatic internal carotid artery stenosis (aICAS) among 121 patients with ICVEs. The degree and length of ICAS as well as plaque echolucency were assessed on ultrasound scans.
Results: A statistically significant inverse correlation between the ultrasound-measured length and degree of ICAS was detected for sICAS≥70% (Spearman correlation coefficient ρ = –0.57, p < 0.001, n = 51) but neither for sICAS<70% (ρ = 0.15, p = 0.45, n = 27) nor for aICAS (ρ = 0.07, p = 0.64, n = 54). The median (IQR) length for sICAS<70% and ≥70% was 17 (15–20) and 15 (12–19) mm (p = 0.06), respectively, while that for sICAS<90% and sICAS 90% was 18 (15–21) and 13 (10–16) mm, respectively (p < 0.001). Among patients with ICAS <70%, a cut-off length of ≥16 mm was found for sICAS rather than aICAS with a sensitivity and specificity of 74.1% and 51.1%, respectively. Irrespective of the stenotic degree, plaques of the sICAS compared to aICAS were significantly more often echolucent (43.2 vs. 24.6%, p = 0.02).
Conclusion: We found a statistically insignificant tendency for the ultrasound-measured length of sICAS<70% to be longer than that of sICAS≥70%. Moreover, the ultrasound-measured length of sICAS<90% was significantly longer than that of sICAS 90%. Among patients with sICAS≥70%, the degree and length of stenosis were inversely correlated. Larger studies are needed before a clinical implication can be drawn from these results.
High-mobility group box 1 protein (HMGB1) is a damage-associated molecular pattern (DAMP) involved in neutrophil extracellular trap (NET) formation and thrombosis. NETs are regularly found in cerebral thromboemboli. We here analyzed associated HMGB1 expression in human thromboemboli retrieved via mechanical thrombectomy from 37 stroke patients with large vessel occlusion. HMGB1 was detected in all thromboemboli, accounting for 1.7% (IQR 0.6–6.2%) of the total thromboemboli area and was found to be colocalized with neutrophils and NETs and in spatial proximity to platelets. Correlation analysis revealed that the detection of HMGB1 was strongly related to the number of neutrophils (r = 0.58, p = 0.0002) and platelets (r = 0.51, p = 0.001). Our results demonstrate that HMGB1 is a substantial constituent of thromboemboli causing large vessel occlusion stroke.
Ischemic stroke caused by thromboembolic occlusion of large cerebral arteries, such as the internal carotid (ICA) and/or the middle cerebral artery (MCA), is treated by mechanical thrombectomy (MT). MT allows salvage of the vessel-occluding thrombemboli, which most frequently originate from the left atrium or the left ventricle of the heart or from sites of plaque rupture within large arteries above the heart. Clot composition may influence the efficacy of (intravenous) thrombolysis and MT, respectively. We analyzed 37 human thrombemboli obtained from acute ischemic stroke patients during MT with special emphasis on histological staining of neutrophils and neutrophil extracellular traps (NETs). We found neutrophils as the main cellular component of cerebral thrombemboli but encountered considerable morphological heterogeneity. Neutrophils accumulated in the border region of fibrin-rich structures indicating possible interaction of neutrophils with distinct structural thrombembolus components. Web-like NETs were found in 35 of 37 thrombemboli in varying amounts. NETs were almost exclusively found within fibrin-rich areas. Importantly, stroke etiology, age and present oral anticoagulation was associated with morphological patterns and the amount of neutrophils. Correlation of histological data and imaging data revealed that relative Hounsfield units of cerebral thrombemboli positively correlated with the amount of red blood cells. In summary, our results demonstrate that neutrophils and NETs are substantial constituents of cerebral thrombemboli and contribute to their structural complexity.
Recurrent medulloblastomas are associated with survival rates <10%. Adequate multimodal therapy is being discussed as having a major impact on survival. In this study, 93 patients with recurrent medulloblastoma treated in the German P-HIT-REZ 2005 Study were analyzed for survival (PFS, OS) dependent on patient, disease, and treatment characteristics. The median age at the first recurrence was 10.1 years (IQR: 6.9–16.1). Median PFS and OS, at first recurrence, were 7.9 months (CI: 5.7–10.0) and 18.5 months (CI: 13.6–23.5), respectively. Early relapses/progressions (<18 months, n = 30/93) found mainly in molecular subgroup 3 were associated with markedly worse median PFS (HR: 2.34) and OS (HR: 3.26) in regression analyses. A significant survival advantage was found for the use of volume-reducing surgery as well as radiotherapy. Intravenous chemotherapy with carboplatin and etoposide (ivCHT, n = 28/93) showed improved PFS and OS data and the best objective response rate (ORR) was 66.7% compared to oral temozolomide (oCHT, n = 47/93) which was 34.8%. Intraventricular (n = 43) as well as high-dose chemotherapy (n = 17) at first relapse was not related to a significant survival benefit. Although the results are limited due to a non-randomized study design, they may serve as a basis for future treatment decisions in order to improve the patients' survival.